Featured News

Persistent gluten exposure is known to lead to lifelong health issues in people with celiac disease, including anemia, malnutrition, and lymphoma. More and more evidence is showing what many have long suspected: maintaining a truly gluten-free diet may not be possible. Despite the need to protect celiac disease patients against gluten exposure, very little is…

ImmunogenX, a clinical stage biotherapeutics company, has published the results of their phase 2 trial testing latiglutenase—an orally administered treatment for celiac disease (CD). Latiglutenase was shown to be safe and effective in reducing the symptoms of seropositive celiac disease patients on a gluten-free diet. A significant improvement in both symptom severity and quality of…

There is currently no easy way to diagnose celiac disease in patients already following a gluten-free diet. In order for celiac disease blood tests to be accurate, patients on a gluten-free diet must undergo a “gluten challenge,” a temporary re-introduction of gluten into the diet, by consuming two slices of wheat-based bread daily for 6-8…

Cour Pharmaceuticals has announced a $420 million licensing deal with Takeda Pharmaceuticals following a favorable outcome of their phase 2 trial for celiac disease. The company released data from a small phase 2a study at the annual United European Gastroenterology organization meeting showing that its treatment, CNP-101, cut levels of inflammation-promoting cytokines. The technology was…

Researchers are collecting blood samples to help develop new diagnostics that may not require gluten ingestion or a biopsy to confirm the diagnosis. 

ActoBio announces FDA has given permission to an Investigational New Drug (IND) application for Actobiotics® AG017, a therapeutic candidate for celiac disease.

On August 13th, 2019, Innovate Biopharmaceuticals, Inc. (Innovate) announced the first patient has been dosed in its Phase 3 clinical trial for patients with celiac disease. The CeD LA 3001 trial is testing larazotide acetate—also known as INN-202—as an adjunct treatment for patients with celiac disease still experiencing symptoms on a gluten-free diet. Larazotide acetate…

Researchers are collecting blood samples to learn more about the antigens that cause certain T cells to trigger intestinal damage in celiac disease patients. Complete a 30-minute study from home & be compensated $50 for your time.

ImmunsanT announces end of its global Phase 2 clinical trial for its Nexvax2 drug candidate. Early results indicate gluten-exposure protection similar to placebo.

If you have celiac disease and currently have kidney stones, or have had kidney stones in the past, you may be eligible for a clinical research study!